메뉴 건너뛰기




Volumn 69, Issue 6, 2017, Pages 1154-1164

Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi-Database Cohort Study

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METHOTREXATE; NITRIC ACID DERIVATIVE; STEROID; TOCILIZUMAB; TOFACITINIB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR;

EID: 85018971196     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.40084     Document Type: Article
Times cited : (164)

References (42)
  • 2
    • 57149096904 scopus 로고    scopus 로고
    • Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies
    • Avina-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008;59:1690–7.
    • (2008) Arthritis Rheum , vol.59 , pp. 1690-1697
    • Avina-Zubieta, J.A.1    Choi, H.K.2    Sadatsafavi, M.3    Etminan, M.4    Esdaile, J.M.5    Lacaille, D.6
  • 3
    • 84982791282 scopus 로고    scopus 로고
    • Impact of disease activity and treatment of comorbidities on the risk of myocardial infarction in rheumatoid arthritis
    • Meissner Y, Zink A, Kekow J, Rockwitz K, Liebhaber A, Zinke S, et al. Impact of disease activity and treatment of comorbidities on the risk of myocardial infarction in rheumatoid arthritis. Arthritis Res Ther 2016;18:183.
    • (2016) Arthritis Res Ther , vol.18 , pp. 183
    • Meissner, Y.1    Zink, A.2    Kekow, J.3    Rockwitz, K.4    Liebhaber, A.5    Zinke, S.6
  • 4
    • 77956503955 scopus 로고    scopus 로고
    • Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity
    • Solomon DH, Kremer J, Curtis JR, Hochberg MC, Reed G, Tsao P, et al. Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Ann Rheum Dis 2010;69:1920–5.
    • (2010) Ann Rheum Dis , vol.69 , pp. 1920-1925
    • Solomon, D.H.1    Kremer, J.2    Curtis, J.R.3    Hochberg, M.C.4    Reed, G.5    Tsao, P.6
  • 6
    • 84922387653 scopus 로고    scopus 로고
    • The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis
    • Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2015;74:480–9.
    • (2015) Ann Rheum Dis , vol.74 , pp. 480-489
    • Roubille, C.1    Richer, V.2    Starnino, T.3    McCourt, C.4    McFarlane, A.5    Fleming, P.6
  • 7
    • 79957461056 scopus 로고    scopus 로고
    • Systematic review and meta-analysis: anti–tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis
    • Barnabe C, Martin BJ, Ghali WA. Systematic review and meta-analysis: anti–tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2011;63:522–9.
    • (2011) Arthritis Care Res (Hoboken) , vol.63 , pp. 522-529
    • Barnabe, C.1    Martin, B.J.2    Ghali, W.A.3
  • 8
    • 79952351318 scopus 로고    scopus 로고
    • Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis
    • Greenberg JD, Kremer JM, Curtis JR, Hochberg MC, Reed G, Tsao P, et al. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis 2011;70:576–82.
    • (2011) Ann Rheum Dis , vol.70 , pp. 576-582
    • Greenberg, J.D.1    Kremer, J.M.2    Curtis, J.R.3    Hochberg, M.C.4    Reed, G.5    Tsao, P.6
  • 9
    • 84880612195 scopus 로고    scopus 로고
    • Cardiovascular risk in rheumatoid arthritis: comparing TNF-α blockade with nonbiologic DMARDs
    • Solomon DH, Curtis JR, Saag KG, Lii J, Chen L, Harrold LR, et al. Cardiovascular risk in rheumatoid arthritis: comparing TNF-α blockade with nonbiologic DMARDs. Am J Med 2013;126:730.e9–17.
    • (2013) Am J Med , vol.126 , pp. 730.e9-17
    • Solomon, D.H.1    Curtis, J.R.2    Saag, K.G.3    Lii, J.4    Chen, L.5    Harrold, L.R.6
  • 10
    • 84923227881 scopus 로고    scopus 로고
    • Tumor necrosis factor-α inhibitor treatment and the risk of incident cardiovascular events in patients with early rheumatoid arthritis: a nested case-control study
    • Desai RJ, Rao JK, Hansen RA, Fang G, Maciejewski M, Farley J. Tumor necrosis factor-α inhibitor treatment and the risk of incident cardiovascular events in patients with early rheumatoid arthritis: a nested case-control study. J Rheumatol 2014;41:2129–36.
    • (2014) J Rheumatol , vol.41 , pp. 2129-2136
    • Desai, R.J.1    Rao, J.K.2    Hansen, R.A.3    Fang, G.4    Maciejewski, M.5    Farley, J.6
  • 11
    • 34848898513 scopus 로고    scopus 로고
    • on behalf of the British Society for Rheumatology Biologics Register. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti–tumor necrosis factor α therapy: results from the British Society for Rheumatology Biologics Register
    • Dixon WG, Watson KD, Lunt M, Hyrich KL, British Society for Rheumatology Biologics Register Control Centre Consortium, Silman AJ, et al, on behalf of the British Society for Rheumatology Biologics Register. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti–tumor necrosis factor α therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007;56:2905–12.
    • (2007) Arthritis Rheum , vol.56 , pp. 2905-2912
    • Dixon, W.G.1    Watson, K.D.2    Lunt, M.3    Hyrich, K.L.4    Silman, A.J.5
  • 12
    • 73449118587 scopus 로고    scopus 로고
    • Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study
    • Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010;69:88–96.
    • (2010) Ann Rheum Dis , vol.69 , pp. 88-96
    • Jones, G.1    Sebba, A.2    Gu, J.3    Lowenstein, M.B.4    Calvo, A.5    Gomez-Reino, J.J.6
  • 13
    • 2642558925 scopus 로고    scopus 로고
    • Treatment of rheumatoid arthritis with humanized anti–interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial
    • Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Treatment of rheumatoid arthritis with humanized anti–interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2004;50:1761–9.
    • (2004) Arthritis Rheum , vol.50 , pp. 1761-1769
    • Nishimoto, N.1    Yoshizaki, K.2    Miyasaka, N.3    Yamamoto, K.4    Kawai, S.5    Takeuchi, T.6
  • 14
    • 40749114497 scopus 로고    scopus 로고
    • Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial
    • Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008;371:987–97.
    • (2008) Lancet , vol.371 , pp. 987-997
    • Smolen, J.S.1    Beaulieu, A.2    Rubbert-Roth, A.3    Ramos-Remus, C.4    Rovensky, J.5    Alecock, E.6
  • 15
    • 85021858218 scopus 로고    scopus 로고
    • Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis
    • Gabay C, McInnes IB, Kavanaugh A, Tuckwell K, Klearman M, Pulley J, et al. Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis. Ann Rheum Dis 2016;75:1806–12.
    • (2016) Ann Rheum Dis , vol.75 , pp. 1806-1812
    • Gabay, C.1    McInnes, I.B.2    Kavanaugh, A.3    Tuckwell, K.4    Klearman, M.5    Pulley, J.6
  • 16
    • 84877275257 scopus 로고    scopus 로고
    • Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial
    • Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R, Pavelka K, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 2013;381:1541–50.
    • (2013) Lancet , vol.381 , pp. 1541-1550
    • Gabay, C.1    Emery, P.2    van Vollenhoven, R.3    Dikranian, A.4    Alten, R.5    Pavelka, K.6
  • 17
    • 84922780682 scopus 로고    scopus 로고
    • An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy
    • Rao VU, Pavlov A, Klearman M, Musselman D, Giles JT, Bathon JM, et al. An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy. Arthritis Rheumatol 2015;67:372–80.
    • (2015) Arthritis Rheumatol , vol.67 , pp. 372-380
    • Rao, V.U.1    Pavlov, A.2    Klearman, M.3    Musselman, D.4    Giles, J.T.5    Bathon, J.M.6
  • 18
    • 84879490766 scopus 로고    scopus 로고
    • US government claims databases
    • In, Strom B, Kimmel S, Hennessy S, editors., 5th ed, Philadelphia, Wiley-Blackwell, p
    • Hennessy S, Freeman C, Cunningham F. US government claims databases. In: Strom B, Kimmel S, Hennessy S, editors. Pharmacoepidemiology. 5th ed. Philadelphia: Wiley-Blackwell; 2012. p. 209–23.
    • (2012) Pharmacoepidemiology , pp. 209-223
    • Hennessy, S.1    Freeman, C.2    Cunningham, F.3
  • 20
    • 84958852771 scopus 로고    scopus 로고
    • A US claims-based analysis of real-world lipid-lowering treatment patterns in patients with high cardiovascular disease risk or a previous coronary event
    • Quek RG, Fox KM, Wang L, Li L, Gandra SR, Wong ND. A US claims-based analysis of real-world lipid-lowering treatment patterns in patients with high cardiovascular disease risk or a previous coronary event. Am J Cardiol 2016;117:495–500.
    • (2016) Am J Cardiol , vol.117 , pp. 495-500
    • Quek, R.G.1    Fox, K.M.2    Wang, L.3    Li, L.4    Gandra, S.R.5    Wong, N.D.6
  • 22
    • 3142651905 scopus 로고    scopus 로고
    • Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records
    • Kiyota Y, Schneeweiss S, Glynn RJ, Cannuscio CC, Avorn J, Solomon DH. Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J 2004;148:99–104.
    • (2004) Am Heart J , vol.148 , pp. 99-104
    • Kiyota, Y.1    Schneeweiss, S.2    Glynn, R.J.3    Cannuscio, C.C.4    Avorn, J.5    Solomon, D.H.6
  • 23
    • 84856025109 scopus 로고    scopus 로고
    • A systematic review of validated methods for identifying cerebrovascular accident or transient ischemic attack using administrative data
    • Andrade SE, Harrold LR, Tjia J, Cutrona SL, Saczynski JS, Dodd KS, et al. A systematic review of validated methods for identifying cerebrovascular accident or transient ischemic attack using administrative data. Pharmacoepidemiol Drug Saf 2012;21 Suppl 1:100–28.
    • (2012) Pharmacoepidemiol Drug Saf , vol.21 Suppl 1 , pp. 100-128
    • Andrade, S.E.1    Harrold, L.R.2    Tjia, J.3    Cutrona, S.L.4    Saczynski, J.S.5    Dodd, K.S.6
  • 24
    • 84922330102 scopus 로고    scopus 로고
    • Validity of claims-based stroke algorithms in contemporary Medicare data: reasons for geographic and racial differences in stroke (REGARDS) study linked with Medicare claims
    • Kumamaru H, Judd SE, Curtis JR, Ramachandran R, Hardy NC, Rhodes JD, et al. Validity of claims-based stroke algorithms in contemporary Medicare data: reasons for geographic and racial differences in stroke (REGARDS) study linked with Medicare claims. Circ Cardiovasc Qual Outcomes 2014;7:611–9.
    • (2014) Circ Cardiovasc Qual Outcomes , vol.7 , pp. 611-619
    • Kumamaru, H.1    Judd, S.E.2    Curtis, J.R.3    Ramachandran, R.4    Hardy, N.C.5    Rhodes, J.D.6
  • 25
    • 51249122241 scopus 로고    scopus 로고
    • Development of a health care utilisation data-based index for rheumatoid arthritis severity: a preliminary study
    • Ting G, Schneeweiss S, Scranton R, Katz JN, Weinblatt ME, Young M, et al. Development of a health care utilisation data-based index for rheumatoid arthritis severity: a preliminary study. Arthritis Res Ther 2008;10:R95.
    • (2008) Arthritis Res Ther , vol.10 , pp. R95
    • Ting, G.1    Schneeweiss, S.2    Scranton, R.3    Katz, J.N.4    Weinblatt, M.E.5    Young, M.6
  • 26
    • 79956217851 scopus 로고    scopus 로고
    • A combined comorbidity score predicted mortality in elderly patients better than existing scores
    • Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol 2011;64:749–59.
    • (2011) J Clin Epidemiol , vol.64 , pp. 749-759
    • Gagne, J.J.1    Glynn, R.J.2    Avorn, J.3    Levin, R.4    Schneeweiss, S.5
  • 27
    • 84869868871 scopus 로고    scopus 로고
    • Supplementing claims data with outpatient laboratory test results to improve confounding adjustment in effectiveness studies of lipid-lowering treatments
    • Schneeweiss S, Rassen JA, Glynn RJ, Myers J, Daniel GW, Singer J, et al. Supplementing claims data with outpatient laboratory test results to improve confounding adjustment in effectiveness studies of lipid-lowering treatments. BMC Med Res Methodol 2012;12:180.
    • (2012) BMC Med Res Methodol , vol.12 , pp. 180
    • Schneeweiss, S.1    Rassen, J.A.2    Glynn, R.J.3    Myers, J.4    Daniel, G.W.5    Singer, J.6
  • 28
    • 0030862072 scopus 로고    scopus 로고
    • Estimating causal effects from large data sets using propensity scores
    • Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997;127:757–63.
    • (1997) Ann Intern Med , vol.127 , pp. 757-763
    • Rubin, D.B.1
  • 30
    • 77958600686 scopus 로고    scopus 로고
    • Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies
    • Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat 2011;10:150–61.
    • (2011) Pharm Stat , vol.10 , pp. 150-161
    • Austin, P.C.1
  • 32
    • 0037207490 scopus 로고    scopus 로고
    • Matched-pair cohort methods in traffic crash research
    • Cummings P, McKnight B, Weiss NS. Matched-pair cohort methods in traffic crash research. Accid Anal Prev 2003;35:131–41.
    • (2003) Accid Anal Prev , vol.35 , pp. 131-141
    • Cummings, P.1    McKnight, B.2    Weiss, N.S.3
  • 34
    • 84874985489 scopus 로고    scopus 로고
    • Researcher allegiance in psychotherapy outcome research: an overview of reviews
    • Munder T, Brutsch O, Leonhart R, Gerger H, Barth J. Researcher allegiance in psychotherapy outcome research: an overview of reviews. Clin Psychol Rev 2013;33:501–11.
    • (2013) Clin Psychol Rev , vol.33 , pp. 501-511
    • Munder, T.1    Brutsch, O.2    Leonhart, R.3    Gerger, H.4    Barth, J.5
  • 35
    • 84938152435 scopus 로고    scopus 로고
    • Association between lipid levels and major adverse cardiovascular events in rheumatoid arthritis compared to non–rheumatoid arthritis patients
    • Liao KP, Liu J, Lu B, Solomon DH, Kim SC. Association between lipid levels and major adverse cardiovascular events in rheumatoid arthritis compared to non–rheumatoid arthritis patients. Arthritis Rheumatol 2015;67:2004–10.
    • (2015) Arthritis Rheumatol , vol.67 , pp. 2004-2010
    • Liao, K.P.1    Liu, J.2    Lu, B.3    Solomon, D.H.4    Kim, S.C.5
  • 36
    • 79951517914 scopus 로고    scopus 로고
    • Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease
    • Myasoedova E, Crowson CS, Kremers HM, Roger VL, Fitz-Gibbon PD, Therneau TM, et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis 2011;70:482–7.
    • (2011) Ann Rheum Dis , vol.70 , pp. 482-487
    • Myasoedova, E.1    Crowson, C.S.2    Kremers, H.M.3    Roger, V.L.4    Fitz-Gibbon, P.D.5    Therneau, T.M.6
  • 37
    • 84883458926 scopus 로고    scopus 로고
    • Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm
    • Robertson J, Peters MJ, McInnes IB, Sattar N. Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm. Nat Rev Rheumatol 2013;9:513–23.
    • (2013) Nat Rev Rheumatol , vol.9 , pp. 513-523
    • Robertson, J.1    Peters, M.J.2    McInnes, I.B.3    Sattar, N.4
  • 38
    • 84954369755 scopus 로고    scopus 로고
    • Association of hyperlipidaemia, inflammation and serological status and coronary heart disease among patients with rheumatoid arthritis: data from the National Veterans Health Administration
    • Navarro-Millán I, Yang S, DuVall SL, Chen L, Baddley J, Cannon GW, et al. Association of hyperlipidaemia, inflammation and serological status and coronary heart disease among patients with rheumatoid arthritis: data from the National Veterans Health Administration. Ann Rheum Dis 2016;75:341–7.
    • (2016) Ann Rheum Dis , vol.75 , pp. 341-347
    • Navarro-Millán, I.1    Yang, S.2    DuVall, S.L.3    Chen, L.4    Baddley, J.5    Cannon, G.W.6
  • 39
    • 33745593028 scopus 로고    scopus 로고
    • Effects of anti-TNF-α treatment on lipid profile in patients with active rheumatoid arthritis
    • Seriolo B, Paolino S, Sulli A, Fasciolo D, Cutolo M. Effects of anti-TNF-α treatment on lipid profile in patients with active rheumatoid arthritis. Ann N Y Acad Sci 2006;1069:414–9.
    • (2006) Ann N Y Acad Sci , vol.1069 , pp. 414-419
    • Seriolo, B.1    Paolino, S.2    Sulli, A.3    Fasciolo, D.4    Cutolo, M.5
  • 40
    • 84956684746 scopus 로고    scopus 로고
    • Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis
    • Zhang J, Xie F, Yun H, Chen L, Muntner P, Levitan EB, et al. Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis. Ann Rheum Dis 2016;75:1813–8.
    • (2016) Ann Rheum Dis , vol.75 , pp. 1813-1818
    • Zhang, J.1    Xie, F.2    Yun, H.3    Chen, L.4    Muntner, P.5    Levitan, E.B.6
  • 41
    • 0142157169 scopus 로고    scopus 로고
    • Evaluating medication effects outside of clinical trials: new-user designs
    • Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003;158:915–20.
    • (2003) Am J Epidemiol , vol.158 , pp. 915-920
    • Ray, W.A.1
  • 42
    • 84933676446 scopus 로고    scopus 로고
    • Active-comparator design and new-user design in observational studies
    • Yoshida K, Solomon DH, Kim SC. Active-comparator design and new-user design in observational studies. Nat Rev Rheumatol 2015;11:437–41.
    • (2015) Nat Rev Rheumatol , vol.11 , pp. 437-441
    • Yoshida, K.1    Solomon, D.H.2    Kim, S.C.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.